Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.

Rachel E CookeNicholas A GherardinSimon J HarrisonHang QuachDale I GodfreyMiles PrinceRachel KoldejDavid S Ritchie

Published in: Journal of translational medicine (2016)

These findings have important implications for the application of this mouse model in the development of MM immunotherapies. Trial registration LitVacc ANZCTR trial ID ACTRN12613000344796; RevLite ANZCTR trial ID NCT00482261.

Keyphrases

phase iii
study protocol
mouse model
phase ii
clinical trial
multiple myeloma
endothelial cells
open label
transcription factor
double blind
placebo controlled